Breakthrough Cancer Vaccine Shows Promise Against Melanoma

A personalized mRNA cancer vaccine combined with the immunotherapy drug Keytruda is showing promising results in preventing high-risk melanoma from returning. Researchers say it is the first personalized cancer vaccine to demonstrate a benefit in a Phase 3 trial. The vaccine is tailored to each patient using mutations identified from their tumor and blood, with additional trial results expected later this year.